News Releases

Year

Sep 10, 2020

UroGen Pharma Announces September 2020 Conference Schedule

PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 10, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will present at the following

Sep 09, 2020

UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth

Diversity of Experience Brings New Insight and Proven Leadership to Support Advanced Commercial Structure While Balancing Continuity in Key Positions Molly Henderson Named Chief Financial Officer Jason Smith Named General Counsel and Chief Compliance Officer Polly A.

Sep 04, 2020

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK --(BUSINESS WIRE)--Sep. 4, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units

Aug 27, 2020

UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence

Trial Did Not Meet Primary Endpoint Believed to be the Result of BOTOX Not Effectively Permeating the Urothelium RTGel Delivered Treatment to the Bladder as Expected with Dwell Time of Up to 10 Hours UroGen and AbbVie will Continue to Explore Use of the RTGel Hydrogel Formulation with AbbVie’s

Aug 10, 2020

UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments

Received U.S. FDA Approval of Jelmyto ® , the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) Successfully Commenced Launch of Jelmyto on June 1 st as Planned; Initial Commercial Performance Demonstrates Strong Execution Announced Positive

Aug 03, 2020

UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

Conference Call and Webcast Scheduled for Monday, August 10, 2020 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Aug. 3, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases, today announced

Jun 05, 2020

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 5, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock

Jun 01, 2020

UroGen Pharma to Present at Jefferies Virtual Healthcare Conference

PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 1, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett , President and Chief Executive Officer,

May 15, 2020

UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer

65% Complete Response in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer Of Patients who Achieved a Complete Response and Underwent an Evaluation at Each Timepoint, 97%, 86% and 85% Remained Disease Free at Six, Nine and 12 Months Following Initiation of Therapy,

May 15, 2020

UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto™ in Patients with Low-Grade Upper Tract Urothelial Cancer

PRINCETON, N.J. --(BUSINESS WIRE)--May 15, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced the presentation of positive data from the UGN-101 ( Jelmyto™ (mitomycin) for pyelocalyceal solution) Phase 3 OLYMPUS trial in patients with low-grade upper tract urothelial cancer (LG-UTUC).

Current page 1
Page 2
Page 3
Next page
Last page

Investors

Investors

News Releases

News Releases

Investors

Investors

Urogen - Investor Relations

News Releases

News Releases

Urogen - Tools

Follow us on